 |
Therapeutic Antibody Fragments |
| |
ESBATech AG is a Zurich, Switzerland-based clinical-stage biotechnology company designing and advancing its proprietary antibody fragments. The company is developing a pipeline of single-chain antibody fragment therapeutics for topical and local delivery resulting in safe and convenient patient initiated therapy.
|
| |
|
|
Latest Company News
Zurich, Switzerland; March 24, 2009
Topical ESBA105 Demonstrates Efficacy in the Back of the Eye to Inhibit Neovascularization
>> read complete press release
Zurich, Switzerland; February 24, 2009
ESBATech’s Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study
>> read complete press release
Zurich, Switzerland; February 3, 2009
ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
>> read complete press release
Mountain View, California; January 26, 2009
Frost & Sullivan Recognizes ESBATech’s Innovation in Developing Antibody Fragments for Biologic Therapeutics
>> read complete press release
|
| |
|
|
|
|
ESBATech AG
Wagistr. 21
CH-8952
Zurich-Schlieren
Switzerland
|
|
|
